For research use only. Not for therapeutic Use.
Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties[1][2][3].
Cycloastragenol (0.03-3 μM; 24-72 hours) promotes viability, osteoblastic differentiation, and mineralization in MC3T3-E1 cells[3].
Cycloastragenol (5, 10, 20 mg/kg) is injected intraperitoneally at the onset of reperfusion, 12 h later and then twice daily for up to three days. Cycloastragenol dose-dependently reduces brain infarct volume, significantly ameliorated functional deficits, and prevents neuronal cell loss in middle cerebral artery occlusion (MCAO) mice. Cycloastragenol suppresses the mRNA expression of pro-inflammatory cytokines, including TNF-α and IL-1β, and inhibits the activation of microglia and astrocytes in the ischemic brain[2].
| Catalog Number | R065888 |
| CAS Number | 78574-94-4 |
| Synonyms | (1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.01,3.03,8.012,16]octadecane-6,9,14-triol |
| Molecular Formula | C30H50O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H50O5/c1-24(2)20(33)8-11-30-16-29(30)13-12-26(5)23(28(7)10-9-21(35-28)25(3,4)34)18(32)15-27(26,6)19(29)14-17(31)22(24)30/h17-23,31-34H,8-16H2,1-7H3/t17-,18-,19-,20-,21-,22-,23-,26+,27-,28+,29-,30+/m0/s1 |
| InChIKey | WENNXORDXYGDTP-UOUCMYEWSA-N |
| SMILES | CC1(C(CCC23C1C(CC4C2(C3)CCC5(C4(CC(C5C6(CCC(O6)C(C)(C)O)C)O)C)C)O)O)C |
| Reference | [1]. Yu Y, et al. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med. 2018;16(3):2175-2182. [2]. Li M, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin. 2020;41(8):1025-1032. [3]. Yu Y, et al. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother. 2020;128:110304. |
